
Barif80 mg
Square Pharmaceuticals PLC.
Febuxostat is a xanthine oxidase inhibitor used for the chronic management of hyperuricemia (high uric acid) in adult patients with gout.
Febuxostat is a xanthine oxidase inhibitor used for the chronic management of hyperuricemia (high uric acid) in adult patients with gout.
Febuxostat is not used to treat an acute gout flare. It is a long-term urate-lowering therapy; starting it can transiently increase the frequency of gout flares due to mobilization of urate crystals from tissue deposits, so flare prophylaxis (e.g. an NSAID or colchicine) is often co-prescribed at initiation.
| Step | Dose |
|---|---|
| Starting dose | 40 mg orally once daily |
| If serum uric acid remains ≥ 6 mg/dL after 2 weeks | Increase to 80 mg orally once daily |
No dose adjustment is needed in mild-to-moderate renal impairment. Data in severe renal impairment are limited; use with caution and physician-guided dose limitation.
No dose adjustment is needed in mild-to-moderate hepatic impairment. Use with caution in severe hepatic impairment, as it has not been well studied.
Safety and efficacy have not been established in pediatric patients; not recommended for use in children.
Febuxostat is contraindicated in the following situations:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.